Brief: Ryvu Therapeutics Recommended For 62.3 Mln Zloty Subsidy For Clinical Trial Of RVU120

Ryvu Therapeutics SA

14/06/2023 06:54

June 14 (Reuters) - Ryvu Therapeutics SA  RVU.WA :
    * SAID ON TUESDAY ITS PROJECT HAS BEEN RECOMMENDED FOR
SUBSIDY BY
POLAND'S MEDICAL RESEARCH AGENCY
    * PROJECT REGARDS CARRYING OUT MULTICENTER, OPEN-LABEL PHASE
II
CLINICAL TRIAL (RIVER-81) EVALUATING SAFETY AND EFFICACY OF
RVU120
    * TOTAL NET VALUE OF PROJECT AMOUNTS TO 133.9 MILLION ZLOTYS
    * RECOMMENDED VALUE OF SUBSIDY AMOUNTS TO 62.3 MILLION
ZLOTYS 
    * PLANNED DURATION OF PROJECT IS SET AT 48 MONTHS

        
 Source text for Eikon:  urn:newsml:reuters.com:*:nEM6Zx350a
 Further company coverage:  RVU.WA  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))